share_log

Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $37

Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $37

瑞士信贷维持Mineralys Therapeutics的表现跑赢大盘,将目标股价下调至37美元
Benzinga ·  2023/08/08 08:16

Credit Suisse analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Outperform and lowers the price target from $38 to $37.

瑞士信贷分析师Richard Law维持Mineralys治疗公司(纳斯达克:MLYS)的表现优于预期,并将目标价从38美元下调至37美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发